Endologix to Present at Three Upcoming Conferences
More News related to ELGX
- Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
- Endologix Receives IDE Approval for Fully Percutaneous Approach to EVAR
- Endologix to Present at Three Upcoming Conferences
- Endologix (ELGX) Tops Q3 EPS by 1c; Guides In-line
- Endologix Reports 47% Third Quarter 2009 Revenue Growth
More News related to PJC
- Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
- Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
- Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
- Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
- Depomed to Present at Piper Jaffray's 21st Annual Health Care Conference
More News related to Press Releases
- H2O Innovation Amends its Stock Option Plan and Grants Stock Options
- Culane Energy Releases 2009 Third Quarter Results
- H2O Innovation Amends its Stock Option Plan and Grants Stock Options
- Russell Breweries Inc. Reports Positive EBITA in Q1 2010 Fiscal Results
- Russell Breweries Inc. Reports Positive EBITA in Q1 2010 Fiscal Results
IRVINE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at three upcoming investor conferences. The first presentation will be at the Canaccord Adams 3rd Annual Cardiovascular Conference at the Nikko Hotel in San Francisco, CA.
Event: Canaccord Adams 3rd Annual Cardiovascular Conference
Date: Tuesday, November 10, 2009
Time: 11:00 a.m. PT
The second presentation will be at the Lazard Capital Markets 6th Annual Healthcare Conference at the St. Regis Hotel in New York City.
Event: Lazard Capital Markets 6th Annual Healthcare Conference
Date: Wednesday, November 18, 2009
Time: 10:00 a.m. ET
The third presentation will be at the Piper Jaffray 21st Annual Health Care Conference at the New York Palace Hotel in New York City.
Event: Piper Jaffray 21st Annual Health Care Conference
Date: Tuesday, December 1, 2009
Time: 2:30 p.m. ET
An audio Web cast of the Company's presentations will be available by visiting the investor relations section of Endologix's Web site at www.endologix.com. A replay of the presentations will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Additional information can be found on Endologix's Web site at www.endologix.com
COMPANY CONTACT: INVESTOR CONTACTS:
---------------- ------------------
Endologix, Inc. The Ruth Group
John McDermott, CEO Nick Laudico (646) 536-7030
(949) 595-7200 Zack Kubow (646) 536-7020
www.endologix.com
SOURCE Endologix, Inc.
Related Categories
Press ReleasesStocks Mentioned
+0.00
-1.92Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
